Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Mellemgaard · SciRah

Researcher profile · Semantic Scholar

A. Mellemgaard

Share profile

A. Mellemgaard — researcher profile on SciRah

h-index: 42
Works: 165
Citations: 11K

Most-cited papers

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
M. Reck, R. Kaiser, A. Mellemgaard, J. Douillard +10 more
2014The Lancet Oncology903 citations Open access
Semantic Scholar
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
J. Mckay, R. Hung, Younghun Han, Xu-Chen Zong +136 more
2017Nature Genetics639 citations Open access
Semantic Scholar
Detection and characterization of lung cancer using cell-free DNA fragmentomes
D. Mathios, J. Johansen, S. Cristiano, J. Medina +34 more
2021Nature Communications406 citations Open access
Semantic Scholar
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
L. Sequist, Ji-Youn Han, M. Ahn, B. Cho +14 more
2020The Lancet Oncology362 citations Open access
Semantic Scholar
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma
T. Choueiri, D. Heng, J. Lee, M. Cancel +8 more
2020JAMA Oncology169 citations Open access
Semantic Scholar
Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment
Anne-Marie Ellegaard, C. Dehlendorff, A. Vind, A. Anand +8 more
2016EBioMedicine135 citations Open access
Semantic Scholar
Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
T. Z. Iversen, L. Engell-Noerregaard, E. Ellebaek, R. Andersen +10 more
2013Clinical Cancer Research124 citations Open access
Semantic Scholar
Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk
Xue-Mei Ji, Y. Bossé, M. T. Landi, J. Gui +120 more
2018Nature Communications76 citations Open access
Semantic Scholar
The prevalence of EGFR mutations in non‐small cell lung cancer in an unselected Caucasian population
B. G. Skov, E. Høgdall, P. Clementsen, M. Krasnik +4 more
2015Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS)72 citations
Semantic Scholar
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
I. J. Eide, Å. Helland, S. Ekman, A. Mellemgaard +5 more
2020Lung Cancer67 citations Open access
Semantic Scholar
The Effect of Different Comorbidities on Survival of Non-small Cells Lung Cancer Patients
M. Iachina, E. Jakobsen, H. Møller, M. Lüchtenborg +3 more
2015Lung66 citations
Semantic Scholar
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
Jin-Ji Yang, Jian Fang, Y. Shu, Jian-Hua Chang +16 more
2020Investigational new drugs64 citations
Semantic Scholar
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
S. Novello, R. Kaiser, A. Mellemgaard, J. Douillard +11 more
2015European Journal of Cancer64 citations Open access
Semantic Scholar
Socioeconomic position and survival after lung cancer: Influence of stage, treatment and comorbidity among Danish patients with lung cancer diagnosed in 2004–2010
S. Dalton, M. Steding‐Jessen, E. Jakobsen, A. Mellemgaard +3 more
2015Acta oncologica63 citations Open access
Semantic Scholar
Role of Comorbidity on Survival after Radiotherapy and Chemotherapy for Nonsurgically Treated Lung Cancer
A. Mellemgaard, M. Lüchtenborg, M. Iachina, E. Jakobsen +3 more
2015Journal of Thoracic Oncology53 citations Open access
Semantic Scholar
Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report
J. Kjeldsen, T. Z. Iversen, L. Engell-Noerregaard, A. Mellemgaard +2 more
2018Frontiers in Immunology46 citations Open access
Semantic Scholar
The Effect of a Home Delivery Meal Service of Energy- and Protein-Rich Meals on Quality of Life in Malnourished Outpatients Suffering from Lung Cancer: A Randomized Controlled Trial
E. Leedo, J. Gade, Sabrina Granov, A. Mellemgaard +3 more
2017Nutrition and Cancer42 citations
Semantic Scholar
EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.
B. Weber, H. Hager, B. Sørensen, T. Mcculloch +4 more
2014Lung Cancer41 citations
Semantic Scholar
Protein-altering germline mutations implicate novel genes related to lung cancer development
Xue-Mei Ji, S. Mukherjee, M. Landi, Y. Bossé +107 more
2020Nature Communications40 citations Open access
Semantic Scholar
Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients
H. Møller, V. Coupland, D. Tataru, M. Peake +8 more
2018Thorax38 citations Open access
Semantic Scholar
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
S. Popat, A. Mellemgaard, K. Fahrbach, Alison Martin +4 more
2015Future Oncology37 citations
Semantic Scholar
Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.
M. Reck, R. Kaiser, A. Mellemgaard, J. Douillard +9 more
2013Journal of Clinical Oncology36 citations
Semantic Scholar
An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer
G. Scagliotti, E. Felip, B. Besse, J. von Pawel +10 more
2013Journal of Thoracic Oncology35 citations Open access
Semantic Scholar
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study
M. Gottfried, J. Bennouna, I. Bondarenko, J. Douillard +10 more
2017Targeted oncology31 citations
Semantic Scholar
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
M. Reck, A. Mellemgaard, J. von Pawel, M. Gottfried +10 more
2015Lung Cancer30 citations
Semantic Scholar
High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer
A. Bondgaard, E. Høgdall, A. Mellemgaard, B. Skov
2014Modern Pathology25 citations
Semantic Scholar
Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
H. Yu, Myung-Ju Ahn, Sang-We Kim, B. Cho +7 more
2019Clinical Trials24 citations
Semantic Scholar
A modified exercise protocol may promote continuance of exercise after the intervention in lung cancer patients—a pragmatic uncontrolled trial
Andreas H. Andersen, A. Vinther, Lise-Lotte Poulsen, A. Mellemgaard
2013Supportive Care in Cancer23 citations
Semantic Scholar
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
I. J. Eide, S. Stensgaard, Å. Helland, S. Ekman +7 more
2021Translational Lung Cancer Research20 citations Open access
Semantic Scholar
Prevalence and management of pulmonary comorbidity in patients with lung and head and neck cancer
M. Gottlieb, Kristoffer Marsaa, N. Godtfredsen, A. Mellemgaard
2015Acta oncologica20 citations Open access
Semantic Scholar
Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
L. Sequist, J. S. Lee, Ji-Youn Han, Wu-Chou Su +8 more
2019Clinical Trials19 citations
Semantic Scholar
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.
S. Popat, A. Mellemgaard, M. Reck, C. Hastedt +1 more
2017Future Oncology19 citations Open access
Semantic Scholar
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
K. Yoh, T. Hirashima, H. Saka, T. Kurata +9 more
2021Targeted oncology15 citations Open access
Semantic Scholar
Procalcitonin and C-reactive protein as markers of bacterial infection in patients with solid tumours.
L. Diness, M. Maraldo, C. Mortensen, A. Mellemgaard +1 more
2014Danish Medical Journal14 citations
Semantic Scholar
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
G. Scagliotti, P. Parikh, J. von Pawel, B. Biesma +16 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar
Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data.
L. Albiges, D. Heng, J. Lee, Stephen Walker +8 more
2022European Journal of Cancer12 citations Open access
Semantic Scholar
Monte Carlo calculations support organ sparing in Deep-Inspiration Breath-Hold intensity-modulated radiotherapy for locally advanced lung cancer.
W. Ottosson, P. Sibolt, Christina Larsen, Jon A. Lykkegaard Andersen +3 more
2015Radiotherapy and Oncology12 citations Open access
Semantic Scholar
Deformable image registration for geometrical evaluation of DIBH radiotherapy treatment of lung cancer patients
W. Ottosson, J. A. Lykkegaard Andersen, S. Borrisova, A. Mellemgaard +1 more
201412 citations Open access
Semantic Scholar
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.
E. Thunnissen, B. Lissenberg-Witte, M. van den Heuvel, K. Monkhorst +31 more
2019Lung Cancer11 citations Open access
Semantic Scholar
Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study
M. Reck, A. Mellemgaard, S. Novello, P. Postmus +3 more
2018OncoTargets and Therapy11 citations Open access
Semantic Scholar
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
B. Gaschler-Markefski, P. Sikken, J. Heymach, M. Gottfried +7 more
2017ESMO Open11 citations Open access
Semantic Scholar
PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study
D. Cronin-Fenton, T. Dalvi, N. Movva, L. Pedersen +8 more
2021Scientific Reports10 citations Open access
Semantic Scholar
Recruiting newly referred lung cancer patients to a patient navigator intervention (PACO): lessons learnt from a pilot study
T. Kjær, A. Mellemgaard, Marianne Stensøe Oksen, Bo Andreassen Rix +3 more
2017Acta oncologica10 citations Open access
Semantic Scholar
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an HLA-A2-restricted epitope derived from indoleamine 2,3 dioxygenase
T. Z. Iversen, L. Engell-Noerregaard, E. Ellebaek, R. Andersen +10 more
2013Journal of Immunotherapy for Cancer10 citations Open access
Semantic Scholar
AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival
Katja Kemp Jacobsen, J. Johansen, A. Mellemgaard, S. Bojesen
2019PLoS ONE9 citations Open access
Semantic Scholar
Prognostic value of ECOG performance status in lung cancer assessed by patients and physicians.
J. Johansen, Mogens K. Boisen, A. Mellemgaard, B. Holm
20139 citations
Semantic Scholar
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, Three‐Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval
Tarjinder Sahota, Corina D. Dota, T. Vik, Wei-Li Yan +7 more
2021Clinical pharmacology in drug development8 citations
Semantic Scholar
Optimizing COPD treatment in patients with lung- or head and neck cancer does not improve quality of life – a randomized, pilot, clinical trial
M. Gottlieb, A. Mellemgaard, Kristoffer Marsaa, N. Godtfredsen
2020European Clinical Respiratory Journal8 citations Open access
Semantic Scholar
Combination immunotherapy with IDO vaccine and PD-1 inhibitors in advanced NSCLC.
A. Mellemgaard, Lotte engel-Norregaard, M. Andersen, M. Zocca +1 more
20177 citations
Semantic Scholar
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
I. J. Eide, H. Grut, Å. Helland, S. Ekman +7 more
2021Acta oncologica6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Reck×9
Invite
M. Reck — researcher profile on SciRah
R. Kaiser×8
Invite
R. Kaiser — researcher profile on SciRah
J. von Pawel×7
Invite
J. von Pawel — researcher profile on SciRah
R. Verheijen×7
Invite
R. Verheijen — researcher profile on SciRah

×6

Invite

M. Gottfried — researcher profile on SciRah

Invite

S. Novello — researcher profile on SciRah

Invite

L. Ottesen — researcher profile on SciRah

J. Douillard×5

Invite

J. Douillard — researcher profile on SciRah

I. Bondarenko×5

Invite

I. Bondarenko — researcher profile on SciRah

Invite

J. Barrueco — researcher profile on SciRah

B. Gaschler-Markefski×5

Invite

B. Gaschler-Markefski — researcher profile on SciRah

Invite

S. Bojesen — researcher profile on SciRah